Analysts Offer Insights on Healthcare Companies: Bellerophon (NASDAQ: BLPH), Spero Therapeutics Inc (NASDAQ: SPRO) and Mirati Therapeutics (NASDAQ: MRTX)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bellerophon (NASDAQ: BLPH), Spero Therapeutics Inc (NASDAQ: SPRO) and Mirati Therapeutics (NASDAQ: MRTX) with bullish sentiments.

Bellerophon (NASDAQ: BLPH)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $5. The company’s shares closed yesterday at $2.17.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.5% and a 48.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Bellerophon has an analyst consensus of Moderate Buy, with a price target consensus of $5.

See today’s analyst top recommended stocks >>

Spero Therapeutics Inc (NASDAQ: SPRO)

H.C. Wainwright analyst Ed Arce initiated coverage with a Buy rating on Spero Therapeutics Inc (NASDAQ: SPRO) today and set a price target of $28. The company’s shares closed yesterday at $11.59.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.6% and a 41.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Conatus Pharmaceuticals, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Spero Therapeutics Inc is Strong Buy and the average price target is $28.50, representing a 145.9% upside.

In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.

Mirati Therapeutics (NASDAQ: MRTX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Mirati Therapeutics (NASDAQ: MRTX), with a price target of $42. The company’s shares closed yesterday at $34.90, close to its 52-week high of $37.62.

According to TipRanks.com, White is a 5-star analyst with an average return of 24.6% and a 50.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Fate Therapeutics.

Currently, the analyst consensus on Mirati Therapeutics is Strong Buy and the average price target is $39.60, representing a 13.5% upside.

In a report issued on May 7, Oppenheimer also assigned a Buy rating to the stock with a $35 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.